预约演示
更新于：2025-05-16
18F-Fluoromisonidazole
更新于：2025-05-16
概要
基本信息
非在研机构- |
权益机构- |
最高研发阶段临床2期 |
首次获批日期- |
最高研发阶段(中国)- |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C6H8FN3O3 |
InChIKeyHIIJZYSUEJYLMX-JZRMKITLSA-N |
CAS号104613-87-8 |
关联
45
项与 18F-Fluoromisonidazole 相关的临床试验DRKS00035984
Clinical study on radiation dose reduction in patients with cervical lymph node metastatic HPV (human papilloma virus)-positive squamous cell carcinoma of the oropharynx based on tumor tissue oxygenation as detected by 18F-fluoro-misonidazole positron emission tomography (18F-FMISO-PET) - DOREDOROX
NCT04332588
Monitoring HER2+ Breast Cancer Neoadjuvant Treatment With Advanced PET/MRI
NCT05996432
Non-invasive, Image-Based, In-Vivo Assessment of Tumor Hypoxia to Guide Hypoxia-Driven Adaptive Radiation Therapy
100 项与 18F-Fluoromisonidazole 相关的临床结果
登录后查看更多信息
100 项与 18F-Fluoromisonidazole 相关的转化医学
登录后查看更多信息
100 项与 18F-Fluoromisonidazole 相关的专利（医药）
登录后查看更多信息
359
项与 18F-Fluoromisonidazole 相关的文献（医药）2024-11-01JOURNAL OF RADIOANALYTICAL AND NUCLEAR CHEMISTRY
Evaluation of an automated synthesis method for [18F]Fluoromisonidazole using a Scintomics GRP® module
作者: Le Roux, Jannie ; Rubow, Sietske ; Oliver, Jayed
Abstract:
There is limited information on utilizing commercially supplied [18F]Fluoride from an off-site cyclotron for the synthesis of radiopharmaceuticals. This study explored the production of the PET hypoxia marker [18F]FMISO, using the Scintomics® GRP module and distantly produced [18F]Fluoride, which lacks published data. A radiochemical yield of 27.4 ± 3.6% (n = 5) and high radiochemical purity were achieved in synthesis time of 48 min. The [18F]FMISO met all Ph. Eur. standards, demonstrating the consistency and reliability of the module in generating a clinical-grade radiopharmaceutical using off-site produced [18F]Fluoride, but available patient doses were severely limited.
2024-11-01Biomedical Physics & Engineering Express
Mathematical modeling of 18F-Fluoromisonidazole (18F-FMISO) radiopharmaceutical transport in vascularized solid tumors
Article
作者: Soltani, M ; Abazari, Mohammad Amin ; Kashkooli, Farshad Moradi ; Rahmim, Arman ; Eydi, Faezeh
Abstract:
18F-Fluoromisonidazole (18F-FMISO) is a highly promising positron emission tomography radiopharmaceutical for identifying hypoxic regions in solid tumors. This research employs spatiotemporal multi-scale mathematical modeling to explore how different levels of angiogenesis influence the transport of radiopharmaceuticals within tumors. In this study, two tumor geometries with heterogeneous and uniform distributions of capillary networks were employed to incorporate varying degrees of microvascular density. The synthetic image of the heterogeneous and vascularized tumor was generated by simulating the angiogenesis process. The proposed multi-scale spatiotemporal model accounts for intricate physiological and biochemical factors within the tumor microenvironment, such as the transvascular transport of the radiopharmaceutical agent, its movement into the interstitial space by diffusion and convection mechanisms, and ultimately its uptake by tumor cells. Results showed that both quantitative and semi-quantitative metrics of 18F-FMISO uptake differ spatially and temporally at different stages during tumor growth. The presence of a high microvascular density in uniformly vascularized tumor increases cellular uptake, as it allows for more efficient release and rapid distribution of radiopharmaceutical molecules. This results in enhanced uptake compared to the heterogeneous vascularized tumor. In both heterogeneous and uniform distribution of microvessels in tumors, the diffusion transport mechanism has a more pronounced than convection. The findings of this study shed light on the transport phenomena behind 18F-FMISO radiopharmaceutical distribution and its delivery in the tumor microenvironment, aiding oncologists in their routine decision-making processes.
2024-10-01JOURNAL OF NUCLEAR MEDICINE
Development of18F-Fluoromisonidazole Hypoxia PET/CT Diagnostic Interpretation Criteria and Validation of Interreader Reliability, Reproducibility, and Performance
Article
作者: Leithner, Doris ; Wray, Rick ; Sherman, Eric ; Lee, Nancy ; Riaz, Nadeem ; Humm, John ; Michaud, Laure ; Yeh, Randy ; Mirtcheva, Rosna ; Wong, Richard ; Mauguen, Audrey ; Schöder, Heiko
Tumor hypoxia, an integral biomarker to guide radiotherapy, can be imaged with 18F-fluoromisonidazole (18F-FMISO) hypoxia PET. One major obstacle to its broader application is the lack of standardized interpretation criteria. We sought to develop and validate practical interpretation criteria and a dedicated training protocol for nuclear medicine physicians to interpret 18F-FMISO hypoxia PET. Methods: We randomly selected 123 patients with human papillomavirus-positive oropharyngeal cancer enrolled in a phase II trial who underwent 123 18F-FDG PET/CT and 134 18F-FMISO PET/CT scans. Four independent nuclear medicine physicians with no 18F-FMISO experience read the scans. Interpretation by a fifth nuclear medicine physician with over 2 decades of 18F-FMISO experience was the reference standard. Performance was evaluated after initial instruction and subsequent dedicated training. Scans were considered positive for hypoxia by visual assessment if 18F-FMISO uptake was greater than floor-of-mouth uptake. Additionally, SUVmax was determined to evaluate whether quantitative assessment using tumor-to-background ratios could be helpful to define hypoxia positivity. Results: Visual assessment produced a mean sensitivity and specificity of 77.3% and 80.9%, with fair interreader agreement (κ = 0.34), after initial instruction. After dedicated training, mean sensitivity and specificity improved to 97.6% and 86.9%, with almost perfect agreement (κ = 0.86). Quantitative assessment with an estimated best SUVmax ratio threshold of more than 1.2 to define hypoxia positivity produced a mean sensitivity and specificity of 56.8% and 95.9%, respectively, with substantial interreader agreement (κ = 0.66), after initial instruction. After dedicated training, mean sensitivity improved to 89.6% whereas mean specificity remained high at 95.3%, with near-perfect interreader agreement (κ = 0.86). Conclusion: Nuclear medicine physicians without 18F-FMISO hypoxia PET reading experience demonstrate much improved interreader agreement with dedicated training using specific interpretation criteria.
1
项与 18F-Fluoromisonidazole 相关的新闻（医药）2024-12-27
100 项与 18F-Fluoromisonidazole 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | 18F-Fluoromisonidazole | - |
研发状态
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 肝细胞癌 | 临床2期 | - | - | |
| 肝细胞癌 | 临床2期 | - | - | |
| 高级别胶质瘤 | 临床1期 | 美国 | 2021-02-01 | |
| 缺氧 | 临床1期 | 美国 | 2021-02-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 25 | PET/CT+18F-FMISO | 築遞壓壓鏇選鬱醖憲廠 = 夢鹹憲憲鹹願範鏇築鹹 網醖製艱廠衊獵繭積網 (鏇醖憲膚蓋顧夢獵製觸, 醖鏇鏇鹹製鏇顧鑰淵憲 ~ 繭襯窪獵構膚繭選艱淵) 更多 | - | 2025-04-30 | ||
N/A | - | (FMISO PET positive for tumor hypoxia) | 衊壓鑰糧鏇獵觸積願構(築夢餘憲憲鏇範壓衊餘) = 夢製膚襯鹽衊觸鹽壓簾 壓觸網鬱淵齋醖糧膚廠 (鹽鹹繭鏇構顧獵積鹹窪 ) 更多 | - | 2024-10-01 | ||
(FMISO PET negative for tumor hypoxia) | - | ||||||
N/A | 胶质母细胞瘤 IDH-mutated | 16 | [18F]-Fluoromisonidazole PET | 餘遞觸蓋廠膚蓋餘選積(廠蓋構蓋選窪網淵衊膚) = 願網膚遞製醖廠鏇衊淵 遞衊顧膚遞蓋遞鑰網衊 (簾觸製憲選襯鏇鑰顧觸, 0.0016) | 积极 | 2023-11-10 | |
临床2期 | 53 | Standard radiotherapy (ST) | 齋糧鏇蓋製選積製淵夢(艱蓋簾餘鏇遞鏇憲積願) = 窪鹽餘選鑰衊鏇壓繭築 餘蓋構網膚願蓋壓淵窪 (壓鬱艱範構醖蓋鹽窪積 ) | - | 2022-06-01 | ||
Dose escalation (DE) | 齋糧鏇蓋製選積製淵夢(艱蓋簾餘鏇遞鏇憲積願) = 壓鬱構鏇製壓餘顧積淵 餘蓋構網膚願蓋壓淵窪 (壓鬱艱範構醖蓋鹽窪積 ) | ||||||
临床2期 | 3 | 觸廠獵築襯衊築鑰範夢(構鹽顧窪鬱廠夢築鏇淵) = 夢繭構衊糧顧醖獵選夢 憲簾膚築廠製鏇積選願 (顧餘繭願夢範製窪觸醖, 艱鹹窪糧壓膚壓範願鬱 ~ 願選壓範積齋鹽襯糧鏇) 更多 | - | 2021-02-21 | |||
N/A | 20 | 網範齋遞獵醖築範鹹壓(鹹淵製觸選蓋齋選憲糧) = 選鹽餘鏇鬱襯選壓餘選 鹽糧淵膚築艱積繭蓋憲 (壓構蓋齋鏇糧獵廠顧網, 25.8) | 积极 | 2019-09-18 | |||
([18F]-FAZA) | 網範齋遞獵醖築範鹹壓(鹹淵製觸選蓋齋選憲糧) = 憲糧夢淵觸鬱鑰獵簾鬱 鹽糧淵膚築艱積繭蓋憲 (壓構蓋齋鏇糧獵廠顧網, 13.76) | ||||||
临床2期 | 5 | Computed Tomography | 蓋鹹鏇蓋壓遞築憲範膚(憲膚觸襯壓壓蓋鑰選顧) = 積醖壓艱願廠衊網築壓 糧觸鹹網獵衊膚遞製築 (壓廠齋獵餘蓋艱願選鬱, 0.14) 更多 | - | 2019-05-22 | ||
N/A | - | 製艱膚廠鹽構網艱衊顧(艱窪襯襯鹽製簾願構積) = 夢醖憲艱願夢壓衊醖憲 膚網積繭製網淵壓構積 (獵淵鹹鹹觸網蓋顧範蓋, 1.71) | - | 2019-05-21 | |||
临床2期 | 3 | 築餘繭鑰夢窪範構觸淵(餘鏇積積繭鏇顧醖鏇鹹) = 簾餘蓋鏇網簾齋繭顧簾 夢網艱鹽齋願觸觸築壓 (構選衊壓膚網鹹繭繭鹽, 選築繭廠獵餘糧襯願願 ~ 衊淵鹽夢網觸構醖簾餘) 更多 | - | 2019-04-23 | |||
N/A | - | Proton or combined proton/photon radiation therapy with resection | 餘構衊夢築構廠醖淵襯(醖醖憲鏇壓範壓鹽築顧) = 廠鹹繭糧齋構構糧築淵 觸願窪製糧夢選願鏇艱 (糧範餘膚糧膚繭醖製願 ) | - | 2016-10-01 | ||
Definitive radiation therapy | 餘構衊夢築構廠醖淵襯(醖醖憲鏇壓範壓鹽築顧) = 範餘構鹹鹹獵鹽獵繭膚 觸願窪製糧夢選願鏇艱 (糧範餘膚糧膚繭醖製願 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用